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Background. Alanine aminotransferase (ALT) ﬂares occur frequently during peginterferon (PEG-IFN)
therapy. We related occurrence of ﬂares to presence of precore (PC) and/or basal core promoter (BCP) mutants
and studied kinetics of hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) levels during ﬂares.
Methods. Fifty of 214 (23%) patients treated with PEG-IFN ± lamivudine for 52 weeks experienced ﬂares.
Flares were host-induced (ALT elevation followed by HBV DNA decline, n = 19), virus-induced (HBV DNA in-
crease with subsequent ALT elevation, n = 17) or indeterminate (n = 14). Presence of wild-type (WT) or non-WT
(detectable PC/BCP mutants) was studied by lineprobe assay.
Results. Fifty-eight percent of host-induced ﬂares occurred in WT HBV patients, whereas 94% of virus-
induced ﬂares occurred in patients with PC and/or BCP mutants (P = .003). HBsAg loss was only achieved in
patients with a host-induced ﬂare, and WT patients with a host-induced ﬂare cleared HBsAg in 64% of cases.
Serum HBsAg levels declined after a host-induced ﬂare, whereas virus-induced ﬂares were accompanied by stable
or increasing levels of HBsAg. Patients with a host-induced ﬂare achieved a mean HBsAg reduction of 3.24 log
IU/mL, compared with 0.25 log IU/mL in virus-induced ﬂares (P < .001). Patients who achieved a decline in
HBsAg of >0.5 log IU/mL within 4 weeks after the ﬂare cleared HBsAg in 64% (7 of 11) of cases.
Conclusions. Host-induced ﬂares are associated with WT virus and may result in decline and clearance of
HBV DNA, HBeAg, and HBsAg. Monitoring of HBsAg levels during and after ﬂares may help predict a favorable
treatment outcome.
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Pegylated interferon (PEG-IFN) is a ﬁrst-line treat-
ment option for hepatitis B e antigen (HBeAg)–
positive chronic hepatitis B but results in a response in
only a limited number of patients [1–3]. Spontaneous
elevations of alanine aminotransferase (ALT), or ﬂares,
are a well-recognized phenomenon in patients treated
with PEG-IFN, although the pathogenesis is not well
understood [4]. Flares may occur in up to 25% of pa-
tients treated with a 1-year course of PEG-IFN and
have been associated with an increased probability of
serological response [5–6]. However, ﬂares can also
have considerable detrimental effects and may result
in hepatic decompensation and death in patients with
advanced cirrhosis [7]. We previously recognized
different types of ﬂares during PEG-IFN therapy of
HBeAg-positive chronic hepatitis B [5, 8]. In that
study, host-induced ﬂares, characterized by an ALT
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ﬂare followed by a decline in hepatitis B virus (HBV) DNA,
were associated with response to treatment, whereas virus-
induced ﬂares, ALT elevations that were preceded by an in-
crease in HBV DNA, were not [5]. Why some patients
develop host-induced ﬂares whereas others experience virus-
induced ﬂares is currently unclear. Acute ﬂares in untreated
chronic hepatitis B patients were recently shown to be associ-
ated with presence of precore (PC) and basal core promoter
(BCP) mutant virus [9]. These mutants are associated with
impaired or absent production of HBeAg and may be less sus-
ceptible to an immune response against HBeAg. Because ALT
ﬂares that are preceded by an increase in HBV DNA levels do
not trigger an effective immune response [10], it is possible
that these virus-induced ﬂares during PEG-IFN therapy are
associated with presence of PC and BCP mutant virus.
It has recently become clear that serum levels of hepatitis B
surface antigen (HBsAg) reﬂect intrahepatic covalently closed
circular DNA and may be a marker for response to PEG-
IFN [11–14]. Monitoring of serum HBsAg levels may, there-
fore, provide additional insight into the differences of host- vs
virus-induced ﬂares and may help identify patients with a
high likelihood of a favorable outcome after ﬂares.
The aims of this study were therefore to (1) relate presence
of PC and BCP mutants before PEG-IFN therapy to occur-
rence of host- or virus-induced ﬂares, (2) study the kinetics of
HBeAg and HBsAg levels during these ﬂares, and (3) investi-
gate whether ALT and HBsAg monitoring can help predict
therapeutic outcome.
PATIENTS AND METHODS
Patients
Patients treated with PEG-IFN alpha-2b alone or in combina-
tion with lamivudine in an investigator-initiated, multicenter,
randomized trial were enrolled into this study [1, 14, 15]. The
inclusion and exclusion criteria for the original trial have pre-
viously been described elsewhere [1]. Patients were HBsAg
positive for at least 6 months before randomization, were
HBeAg positive, had elevated serum ALT levels of >2 but <10
times the upper limit of normal, and had a serum HBV DNA
concentration of >1.0 × 105 copies/mL. Patients were treated
with 100 μg of PEG-IFN alpha-2b weekly (PegIntron, Scher-
ing-Plough) in combination with placebo or 100 mg of lami-
vudine (Zefﬁx, GlaxoSmithKline) daily for 52 weeks. Of the
266 patients in the original study, 214 had available data on
baseline presence of PC and/or BCP mutants. The study was
conducted in accordance with the guidelines of the Declara-
tion of Helsinki and the principles of good clinical practice.
All patients gave written informed consent according to the
standards of the local ethics committees.
Laboratory Measurements
Presence of PC and BCP mutants was assessed using the
INNO-LiPAHBV PreCore assay (Innogenetics). This line probe
assay allows for easy detection of PC (at nucleotide position
G1896) and BCP (at nucleotide positions A1762 and G1764)
mutants, even when only present as minority species [16].
Patients were subsequently classiﬁed as having wild-type (WT;
only WT virus detectable) virus, or non-WT (PC, BCP, or
both mutants detectable) virus. Serum HBV DNA, HBeAg,
and HBsAg were quantiﬁed in samples taken at baseline,
during treatment, and during 6 months of off-treatment
follow-up. Patients were seen at the outpatient clinic at least
every 4 weeks during the study. HBV DNA quantiﬁcation was
performed using an in-house–developed TaqMan polymerase
chain reaction assay (lower limit of quantiﬁcation, 400 copies/
mL) based on the EuroHep standard [17]. HBsAg and HBeAg
were measured using the Roche ELECSYS assay using a quan-
titative protocol (Roche Diagnostics).
Classiﬁcation of Flares
A ﬂare was deﬁned as a 3-fold increase in serum ALT com-
pared with baseline levels [5]. The time point of the ﬂare was
deﬁned as the time of the peak level of serum ALT. If a
patient experienced multiple ﬂares, the ﬁrst was used for clas-
siﬁcation. Two types of ﬂares were recognized, as described
previously by Flink et al [5]. A ﬂare was designated as virus-
induced when the ALT peak was preceded by at least a 1 log
increase in HBV DNA levels within 4 months. Host-induced
ﬂares were characterized as an ALT peak without a preceding
increase in HBV DNA and were typically followed by a subse-
quent decrease in HBV DNA of at least 1 log within the next
4 months. Flares that could not be classiﬁed were designated
indeterminate [5].
Statistical Analysis
Associations between variables were tested using Student t
test, χ2 test, Pearson correlation test, or their nonparametric
equivalents when appropriate. SPSS version 15.0 (SPSS Inc)
and the SAS 9.2 program (SAS Institute Inc) were used to
perform statistical analyses. All statistical tests were 2-sided
and were evaluated at the .05 level of signiﬁcance.
RESULTS
Patient Characteristics
Flares occurred in 50 of 214 patients with available PC and/or
BCP data (23%). The characteristics of patients with a host-
induced, virus-induced, or indeterminate ﬂare are shown in
Table 1. The frequency of ﬂares was similar for patients with
WT virus when compared with those with PC and/or BCP
mutants (25% vs 23%; P = .68).
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Relationship Between Type and Timing of Flare and Presence of
PC and BCP Mutants
The type of ﬂare differed according to presence of mutants;
host ﬂares occurred predominantly in patients with WT virus
(58%), whereas virus-induced ﬂares almost always occurred in
patients with non-WT virus (16 of 17; 94%). Of the 76 pa-
tients with WT virus, 11 (14%) experienced a host-induced
ﬂare, compared with 6% of patients with non-WT virus
(P = .03). Conversely, 12% of non-WT virus patients experi-
enced a virus-induced ﬂare, compared with only 1 of 76 (1%)
of WT virus patients (P = .008). Of the 25 (50%) ﬂares that
occurred during treatment, 15 (60%) occurred in patients with
WT virus. Interestingly, the timing of the ﬂare was also associ-
ated with presence of WT or non-WT virus (P = .004)
(Figure 1). Presence of PC and/or BCP mutants at baseline
was independently associated with the occurrence of a virus-
induced ﬂare; this remained true after adjustment for HBV ge-
notype, patient age, and use of combination therapy (adjusted
odds ratio for virus induced ﬂare, 7.04; P = .02).
Relationship Between Type of Flare, Presence of Mutants, and
Response at Week 78
Host-induced ﬂares resulted more frequently in HBeAg loss
than virus-induced ﬂares (58% vs 12%; P = .001). HBeAg loss
with HBV DNA levels <10 000 copies/mL and HBsAg clear-
ance were achieved in 42% of patients with a host-induced
ﬂare, and in none of the patients with virus-induced or inde-
terminate ﬂares (P < .001). HBV DNA undetectability was ob-
served in 5 (26%) patients with a host-induced ﬂare,
compared with zero patients with other types of ﬂares
Table 1. Characteristics of the Study Cohort
Characteristics
Flare
No Flare (n = 164) P ValueHost (n = 19) Virus (n = 17) Indeterminate (n = 14)
Demography
Mean age, (SD), y 42 (12.8) 27 (9.8) 34 (11.4) 33.5 (12.4) .005
Male 15 (79%) 14 (82%) 12 (86%) 126 (77%) .85
PEG-IFN monotherapy 7 (37%) 3 (18%) 14 (100%) 80 (49%) <.001
Race .22
Caucasian 15 (79%) 14 (82%) 8 (57%) 120 (73%)
Asian 1 (5%) 1 (6%) 4 (29%) 34 (21%)
Other 3 (16%) 2 (12%) 2 (14%) 10 (6%)
Laboratory results
Mean (SD) ALTa 3.1 (1.3) 3.2 (1.7) 2.6 (1.0) 4.7 (3.3) .005
Mean (SD) HBV DNA, log c/mL 9.3 (0.5) 9.2 (1.1) 9.3 (0.6) 9.1 (0.9) .51
Mean (SD) HBsAg, log IU/mL 4.6 (0.4) 4.4 (0.7) 4.4 (0.5) 4.4 (0.6) .38
Mean (SD) HBeAg, log IU/mL 2.5 (0.9) 2.2 (0.8) 2.6 (0.6) 2.5 (0.7) .55
HBV genotype .04
A 12 (63%) 2 (12%) 5 (36%) 55 (34%)
B 2 (11%) 2 (12%) 0 (0%) 15 (9%)
C 0 (0%) 1 (6%) 4 (29%) 24 (15%)
D 4 (21%) 12 (71%) 4 (29%) 65 (40%)
Other/mixed 1 (5%) 0 (0%) 1 (7%) 5 (3%)
Previous IFN therapy 3 (16%) 5 (29%) 2 (14%) 28 (17%) .62
INNO-LiPA PreCore result .007
Wild type 11 (58%) 1 (6%) 7 (50%) 57 (35%)
Non-wild type 8 (42%) 16 (94%) 7 (50%) 107 (65%)
Response
HBeAg loss 11 (58%) 2 (12%) 1 (7%) 63 (38%) .003
Combined responseb 8 (42%) 0 (0%) 0 (0%) 33 (20%) .003
HBsAg loss 8 (42%) 0 (0%) 0 (0%) 9 (6%) <.001
Abbreviations: ALT, alanine aminotransferase; HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; IFN, interferon; PEG-IFN,
peginterferon; SD, standard deviation.
a Multiples of upper limit of the normal range.
b HBeAg loss and HBV DNA <10 000 copies/mL at week 78.
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(P = .01). Importantly, in the subgroup of WT virus patients
with a host-induced ﬂare (n = 11), HBsAg clearance was
achieved in 64% of patients (7 of 11; P < .001).
Monitoring of HBeAg and HBsAg Levels During Flares in
Individual Patients
We analyzed individual patients’ changes in ALT, HBV DNA,
HBeAg, and HBsAg monthly during PEG-IFN therapy and up
to 6 months post-treatment. As shown in Figure 2A and 2B,
host-induced ﬂares were characterized by a steep ALT ﬂare,
followed by pronounced declines of HBV DNA, HBeAg, and
HBsAg. In contrast, virus-induced ﬂares typically showed an
increase in HBV DNA before ALT elevation, and serum levels
of HBeAg and HBsAg either remained stable (Figure 2C) or
temporarily increased (Figure 2D).
Figure 1. Proportion of patients with wild-type (WT) or precore (PC)
and/or basal core promoter (BCP) mutants according to the timing of the
ﬂare. Twenty-one patients experienced a ﬂare before week 24, 4 experi-
enced a ﬂare between week 24 and 52, and 25 experienced a ﬂare
between week 52 and the end of the study (off-treatment).
Figure 2. Kinetics of alanine aminotransferase (ALT), hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg), and hepatitis B surface antigen
(HBsAg) in 2 patients with a host-induced ﬂare (A and B ) and in 2 patients with a virus-induced ﬂare (C and D ). HBV DNA is given in log copies/mL;
HBeAg and HBsAg are given in log IU/mL; and ALT is given in times upper limit of normal.
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Pronounced HBsAg Decline in Patients With a Host-Induced
Flare
Only patients with a host-induced ﬂare achieved substantial
HBV DNA decline by week 78 (HBV DNA decline from base-
line was 4.21, 1.51, and 0.58 log copies/mL in patients with
host-induced, virus-induced, or indeterminate ﬂares, respec-
tively; P < .001). Importantly, similar HBeAg reductions were
achieved in patients with host- and virus-induced ﬂares,
whereas only patients with a host-induced ﬂare achieved a
pronounced HBsAg decline at 6 months post-treatment.
HBeAg declines were 0.84, 1.02, and 0.25 log IU/mL at week
78 (P = .31) in patients with a host-induced, virus-induced, or
indeterminate ﬂare, compared with HBsAg declines of 3.24,
0.25, and 0.31 log IU/mL, respectively (P < .001).
HBsAg Decline After Flare Predicts HBsAg Clearance
Mean HBsAg levels at the peak of ALT during the ﬂare were
similar in patients with a host-induced, virus-induced, or in-
determinate ﬂare (P = .56). However, pronounced HBsAg de-
clines immediately after the ﬂare were achieved only in
patients with a host-induced ﬂare: mean declines were 0.78
and 1.29 log IU/mL at 1 and 2 months, after the ALT peak,
respectively, in patients with a host-induced ﬂare. This con-
trasted strongly with the stable levels of HBsAg observed in
patients with a virus-induced or an indeterminate ﬂare (mean
increase 2 months after ALT peak was 0.02 and 0.16 log IU/mL,
respectively; P = .002). The probability of an HBsAg decline of
at least 0.5 log IU/mL was 53% in patients with a host-
induced ﬂare, 8% in patients with a virus-induced ﬂare, and
7% in patients with an indeterminate ﬂare (P = .003). Patients
who achieved a decline of >0.5 log IU/mL during the ﬁrst
month after the peak of the ﬂare had a probability of HBsAg
clearance of 64% (7 of 11), increasing to 75% (6 of 8) in pa-
tients with a decline >1 log IU/mL (P < .001 for both).
DISCUSSION
This study shows that host-induced ﬂares occur more frequently
in patients with only WT virus and result in pronounced de-
clines of HBsAg levels. Frequent monitoring of serum HBsAg
levels during ﬂares may help predict a favorable outcome.
Spontaneous elevations of ALT are frequently encountered in
the natural history of chronic hepatitis B and may herald pro-
gression from the immunotolerant phase of HBV infection to
immune clearance and eventual HBeAg seroconversion [18].
However, ﬂares that occur during or after discontinuation of
nucleo(s)tide analogues therapy hardly ever lead to virological
remission and may result in hepatic decompensation [19, 20].
Flares that occur after nucleo(s)tide analogue discontinuation do
not trigger an adequate immune response [10], suggesting these
ﬂares are different from ﬂares that induce disease remission in
untreated patients. Flink et al. showed that different types of
ﬂares occur during PEG-IFN therapy and showed that where
host-induced ﬂares frequently resulted in therapy response,
virus-induced ﬂares did not [5]. This study shows that these
virus-induced ﬂares occur more frequently in patients where PC
and BCP mutants are present before PEG-IFN initiation.
Because these mutants have a reduced production of HBeAg,
they are less susceptible to a PEG-IFN–induced immune re-
sponse against HBeAg, which could result in positive selection
and a subsequent virus-induced ﬂare not unlike those observed
in patients with viral breakthrough during nucleo(s)tide ana-
logue–based therapy [19]. A relationship between type of ﬂare
and the host immune system should also be investigated. It has
been shown that ﬂares that do not result in viral clearance may
result in hepatic decompensation or death and that presence of
PC and BCP mutants may more frequently be found in patients
suffering from such acute exacerbations [4, 19, 21]. Given that
patients with detectable PC and BCP mutants before PEG-IFN
initiation are unlikely to achieve a virological response [22] and
are more likely to experience virus-induced ﬂares, it appears that
patients with PC and BCP mutants are less suitable candidates
for PEG-IFN therapy.
Several studies have shown that the serum level of HBsAg is
a good marker for immune control, both in the natural history
and during PEG-IFN therapy [12]. Levels of HBsAg are a
proxy for intrahepatic transcriptionally active covalently closed
circular DNA, and a reduction in HBsAg levels may signify a
decrease in intrahepatic covalently closed circular DNA and in-
duction of immune control over HBV [12]. In this study, host-
induced ﬂares resulted in pronounced HBsAg declines that
were sustained during post-treatment follow-up. Importantly,
close monitoring of serum HBsAg levels during ﬂares revealed
that the effect of host-induced ﬂares in reducing serum HBsAg
levels was apparent even on the individual patient level. It was
also clear that virus-induced ﬂares do not result in a reduction
of serum HBsAg levels, which is in line with the low response
rates observed in these patients. Furthermore, the induction of
a decline in serum HBsAg levels during a ﬂare appears to
herald HBsAg clearance, suggesting that monitoring of HBsAg
levels in patients experiencing ﬂares during PEG-IFN therapy
may give valuable information on a patient’s probability of
treatment response. We propose to use frequent monitoring of
serum HBsAg because it is relatively inexpensive, may provide
information on response to PEG-IFN therapy [3, 14], and can
help predict outcome of ﬂares. A decline in HBsAg levels
during the ﬁrst months after the ﬂare may identify patients
with a very high likelihood of HBsAg loss.
Importantly, our ﬁndings were also valid when extending
the window for HBV DNA increase or decline from 4 to 6
months before or after the ﬂare and when increasing the ALT
level from 3 times to >4 times the level at baseline.
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In conclusion, host-induced ﬂares during PEG-IFN therapy
may result in HBsAg decline and subsequent clearance,
whereas virus-induced ﬂares do not. Monitoring of serum
HBsAg levels in patients with ﬂares may help identify patients
with a high likelihood of subsequent HBsAg clearance.
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